申联生物(688098) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was RMB 288.27 million, a decrease of 4.99% compared to the previous year[3] - Net profit attributable to the parent company was a loss of RMB 19.09 million, a reduction in loss of 57.33% year-over-year[6] - Basic earnings per share for the reporting period were RMB -0.05, an improvement from RMB -0.11 in the previous year[3] - The weighted average return on net assets was -1.36%, an improvement from -3.07% year-over-year[3] Assets and Investments - Total assets at the end of the reporting period were RMB 1,543.06 million, a decrease of 0.71% from the beginning of the year[6] - The company invested in a stake in the innovative drug company Yangzhou Shizhi Source Biotechnology Co., Ltd., which is conducting clinical research on innovative drugs[7] - The company plans to gain controlling interest in Yangzhou Shizhi Source through its wholly-owned subsidiary, enhancing its capabilities in human innovative drug development[7] Business Strategy and Development - The company has made progress in product development, launching new vaccines such as the swine fever recombinant subunit vaccine and the dual vaccine for swine streptococcus and infectious pleuropneumonia[7] - The company has adjusted its business strategy to focus on customer needs, leading to a significant reduction in total expenses compared to the previous year[7] Risk Awareness - The company emphasizes the importance of risk awareness as the financial data is preliminary and unaudited[10]